Head
Complement Biology
Complement Biology, New York Blood Center
United States of America
"Dr. Debnath's research focus is to identify new antiviral drugs by state-of-the art drug design methods. Ongoing projects include: Identification of small molecule entry inhibitors that target specifically HIV-1 envelope glycoprotein gp120 and disrupt it’s binding to the T-cell surface receptor CD4. Identification of the best combination of latency reversing agents (LRAs) to facilitate eradication of HIV-1 from virus reservoirs by drugs, antibody drug conjugates (ADC) or immune system. This is expected to help in achieving functional cure of HIV-1. Identification of novel agents for pathogen inactivation of blood products."
Virology